Abstract
AbstractThe COVID-19 vaccine has been a miraculous, life-saving advance, offering staggering efficacy in adults, and was developed with astonishing speed. The time from sequencing the virus to authorizing the first COVID-19 vaccine was so brisk even the optimists appear close-minded. Yet, simultaneously, United States’ COVID-19 vaccination roll-out and related policies have contained missed opportunities, errors, run counter to evidence-based medicine, and revealed limitations in the judgment of public policymakers. Misplaced utilization, contradictory messaging, and poor deployment in those who would benefit most—the elderly and high-risk—alongside unrealistic messaging, exaggeration, and coercion in those who benefit least—young, healthy Americans—is at the heart. It is important to consider the history of COVID-19 vaccines to identify where we succeeded and where we failed, and the effects that these errors may have more broadly on vaccination hesitancy and routine childhood immunization programs in the decades to come.
Publisher
Springer Science and Business Media LLC
Reference120 articles.
1. @VPrasadMDMPH (Vinay Prasad). 2021. Yesterday I said the J&J vaccine is Game Over for women 18–50, with 6 cases in 1.4 million vaccinated in that age group (~1/200k), here is why I say that.... Twitter. https://twitter.com/vprasadmdmph/status/1382734864219140100.
2. Andrews, N., E. Tessier, J. Stowe, C. Gower, F. Kirsebom, R. Simmons, E. Gallagher, S. Thelwall, N. Groves, G. Dabrera, R. Myers, C.N.J. Campbell, G. Amirthalingam, M. Edmunds, M. Zambon, K. Brown, S. Hopkins, M. Chand, S.N. Ladhani, and J. Lopez Bernal. 2022. Duration of protection against mild and severe disease by covid-19 vaccines. The New England Journal of Medicine 386 (4): 340–350. https://doi.org/10.1056/NEJMoa2115481.
3. Approval letter: BNT162b2. 2021.
4. Australian Government. 2023. COVID-19 booster vaccine advice. Australian Government Department of Health and Aged Care. https://www.health.gov.au/our-work/covid-19-vaccines/getting-your-vaccination/booster-doses
5. Baden, L. R., H. M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemert, S. A. Spector, N. Rouphael, C. B. Creech, J. McGettigan, S. Khetan, N. Segall, J. Solis, A. Brosz, C. Fierro, H. Schwartz, K. Neuzil, L. Corey, COVE Study Group. 2021. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. The New England Journal of Medicine, 384(5), 403–416. https://doi.org/10.1056/NEJMoa2035389.